• Molecular NameTipranavir
  • Synonymtipranavir; TPV
  • Weight602.674
  • Drugbank_IDDB00932
  • ACS_NO174484-41-4
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)7.14
  • pkaN/A
  • LogD (pH=7, predicted)7.1
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-4.04
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds12
  • TPSA113.97
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyIt is administered with ritonavir in combination therapy to treat HIV infection
  • Absorption_valueN/A
  • Absorption (description)Absorption is limited, although no absolute quantification of absorption is available.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.9
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.
  • Half life5~6 h
  • ExcretionFecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
  • LD50 (rat)LD50>5,000 mg/kg
  • LD50 (mouse)N/A